tbuckley/cabot-search huggingface dataset:
Reducing Hypermuscularization of the Transitional Segment Between Arterioles and Capillaries Protects Against Spontaneous Intracerebral Hemorrhage
Authors: Julien Ratelade, Nicholas R. Klug, Damiano Lombardi, Monara Kaelle Servulo Cruz Angelim, Fabrice Dabertrand, Valérie Domenga-Denier, Rustam Al-Shahi Salman, Colin Smith, Jean-Frédéric Gerbeau, Mark T. Nelson, Anne Joutel
Journal: Circulation (2020)

Spontaneous deep intracerebral hemorrhage (ICH) is a devastating subtype of stroke without specific treatments. It has been thought that smooth muscle cell (SMC) degeneration at the site of arteriolar wall rupture may be sufficient to cause hemorrhage. However, deep ICHs are rare in some aggressive small vessel diseases that are characterized by significant arteriolar SMC degeneration. Here we hypothesized that a second cellular defect may be required for the occurrence of ICH.We studied a genetic model of spontaneous deep ICH using Col4a1+/G498V and Col4a1+/G1064D mouse lines that are mutated for the α1 chain of collagen type IV. We analyzed cerebroretinal microvessels, performed genetic rescue experiments, vascular reactivity analysis, and computational modeling. We examined postmortem brain tissues from patients with sporadic deep ICH.We identified in the normal cerebroretinal vasculature a novel segment between arterioles and capillaries, herein called the transitional segment (TS), which is covered by mural cells distinct from SMCs and pericytes. In Col4a1 mutant mice, this TS was hypermuscularized, with a hyperplasia of mural cells expressing more contractile proteins, whereas the upstream arteriole exhibited a loss of SMCs. TSs mechanistically showed a transient increase in proliferation of mural cells during postnatal maturation. Mutant brain microvessels, unlike mutant arteries, displayed a significant upregulation of SM genes and Notch3 target genes, and genetic reduction of Notch3 in Col4a1+/G498V mice protected against ICH. Retina analysis showed that hypermuscularization of the TS was attenuated, but arteriolar SMC loss was unchanged in Col4a1+/G498V, Notch3+/- mice. Moreover, hypermuscularization of the retinal TS increased its contractility and tone and raised the intravascular pressure in the upstream feeding arteriole. We similarly found hypermuscularization of the TS and focal arteriolar SMC loss in brain tissues from patients with sporadic deep ICH.Our results suggest that hypermuscularization of the TS, through increased Notch3 activity, is involved in the occurrence of ICH in Col4a1 mutant mice, by raising the intravascular pressure in the upstream feeding arteriole and promoting its rupture at the site of SMC loss. Our human data indicate that these 2 mutually reinforcing vascular defects may represent a general mechanism of deep ICH.
POGO STICKING AND LVAD SQUEAKING! TORSION OF A HEARTMATE 3 OUTFLOW CANNULA AFTER JUMPING ON A POGO STICK
Authors: Adrian DaSilva-DeAbreu, Juan Pablo Rodriguez-Escudero, Aditya Bansal, Clement Eiswirth, Selim Krim, Hamang Patel, Hector O. Ventura, Sapna Desai, Stacy Mandras
Journal: Journal of the American College of Cardiology (2020)
QRS SHORTENING AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE: PREDICTORS OF ECHOCARDIOGRAPHIC RESPONSE TO RESYNCHRONIZATION THERAPY IN WOMEN
Authors: Margarida Pujol Lopez, Dimitrios Varrias, Eduard Guasch, Jose M Tolosana, Lluís Mont, E. Kevin Heist, Jagmeet P. Singh, Saumya Das
Journal: Journal of the American College of Cardiology (2020)
THE IMPACT OF AMERICAN-STYLE FOOTBALL PARTICIPATION ON VENTRICULAR-ARTERIAL COUPLING
Authors: Jason Tso, Casey Hollowed, Chang Liu, Ahmed AlBadri, Ayman Alkhoder, Morgan Dommisse, Zaina Gowani, Arthur Miller, Grace Nguyen, Parker Nguyen, Ganesh Prabakaran, Arianna Sidoti, Mohamad Wehbe, Angelo Galante, Carla Gilson, Craig Clark, Thomas Marshall, Gene Patterson, Yi-An Ko, Arshed A. Quyyumi, Jonathan Kim
Journal: Journal of the American College of Cardiology (2020)
Cardiovascular Corner—Stable Coronary Artery Disease, An LDL “Vaccine,” and Anti-inflammatories
Authors: Jennifer Abbasi
Journal: JAMA (2020)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EFFECT OF BISOPROLOL TRANSDERMAL PATCH ON REDUCING EARLY RECURRENCE DURING THE BLANKING PERIOD AFTER ATRIAL FIBRILLATION ABLATION
Authors: Yuya Suzuki, Masaru Kuroda, Tomoo Fujioka, Masayuki Kintsu, Yuichiro Miyazaki, Tsubasa Noda, Takeshi Matsuura, Yasutaka Hirayama, Akira Matsuura, Masahito Kawata
Journal: Journal of the American College of Cardiology (2020)
Hydrogel-forming microneedle arrays as a therapeutic option for transdermal esketamine delivery
Authors: Aaron J. Courtenay, Emma McAlister, Maelíosa T.C. McCrudden, Lalit Vora, Lilach Steiner, Galit Levin, Etgar Levy-Nissenbaum, Nava Shterman, Mary-Carmel Kearney, Helen O. McCarthy, Ryan F. Donnelly
Journal: Journal of Controlled Release (2020)

Treatment resistant depression is, by definition, difficult to treat using standard therapeutic interventions. Recently, esketamine has been shown as a viable rescue treatment option in patients in depressive crisis states. However, IV administration is associated with a number of drawbacks and advanced delivery platforms could provide an alternative parenteral route of esketamine dosing in patients. Hydrogel-forming microneedle arrays facilitate transdermal delivery of drugs by penetrating the outer layer of the skins surface, absorbing interstitial skin fluid and swelling. This subsequently facilitates permeation of medicines into the dermal microcirculation. This paper outlines the in vitro formulation development for hydrogel-forming microneedle arrays containing esketamine. Analytical methods for the detection and quantitation of esketamine were developed and validated according to International Conference on Harmonisation standards. Hydrogel-forming microneedle arrays were fully characterised for their mechanical strength and skin insertion properties. Furthermore, a series of esketamine containing polymeric films and lyophilised reservoirs were assessed as drug reservoir candidates. Dissolution testing and content drug recovery was carried out, followed by permeation studies using 350 μm thick neonatal porcine skin in modified Franz cell apparatus. Lead reservoir candidates were selected based on measured physicochemical properties and brought forward for testing in female Sprague-Dawley rats. Plasma samples were analysed using reverse phase high performance liquid chromatography for esketamine. Both polymeric film and lyophilised reservoirs candidate patches achieved esketamine plasma concentrations higher than the target concentration of 0.15–0.3 μg/ml over 24 h. Mean plasma concentrations in rats, 24 h post-application of microneedle patches with drug reservoir F3 and LW3, were 0.260 μg/ml and 0.498 μg/ml, respectively. This developmental study highlights the potential success of hydrogel-forming microneedle arrays as a transdermal drug delivery platform for ESK and supports moving to in vivo tests in a larger animal model.
ULTRASOUND GUIDED AXILLARY VEIN ACCESS: AN ALTERNATIVE APPROACH FOR VENOUS ACCESS FOR CARDIAC DEVICE IMPLANTATION
Authors: Jonathan Chandler, Nachiket Apte, John Fritzlen, Robert Weidling, Sean Lacy, Arslan Naeem, Madhu Reddy, Rigoberto Ramirez, Martin Emert, Loren Berenbom, Rhean Linette Pimentel, Raghuveer Dendi, Seth H. Sheldon
Journal: Journal of the American College of Cardiology (2020)
ASSOCIATION OF ACUTE KIDNEY INJURY WITH NEURODEVELOPMENTAL OUTCOMES IN INFANTS UNDERGOING SURGERY FOR CONGENITAL HEART DISEASE
Authors: Chetna Pande, Lisa Noll, Faridis Serrano, Natasha Afonso, Sonia Monteiro, Kriti Puri, Ayse A. Arikan, Lara Shekerdemian
Journal: Journal of the American College of Cardiology (2020)
18F-SODIUM FLUORIDE CORONARY UPTAKE PREDICTS MYOCARDIAL INFARCTIONS IN PATIENTS WITH KNOWN CORONARY ARTERY DISEASE
Authors: Jacek Kwiecinski, Evangelos Tzolos, Sebastien Cadet, Philip D. Adamson, Alastair Moss, Nikhil Vilas Joshi, Edwin Van Beek, Michelle Williams, Daniel S. Berman, David E. Newby, Marc Dweck, Piotr Slomka
Journal: Journal of the American College of Cardiology (2020)
ACCURACY OF APPLE WATCH HEART RATE MEASUREMENTS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA AND ATRIAL FIBRILLATION
Authors: Pauline Huynh, Rongzi Shan, Ngozi Osuji, Jie Ding, Francoise Marvel, Garima Sharma, Seth Shay Martin
Journal: Journal of the American College of Cardiology (2020)
Abstract 14404: Plasma Xanthine Oxydoreductase (XOR) Activity is Extremely High Inpatients With Severely Decompensated Acute Heart Failure Who Require Intensive Care
Authors: Hirotake Okazaki, Akihiro Shirakabe, Masato Matsushita, Yusaku Shibata, Tomofumi Sawatani, Saori Uchiyama, Kenichi Tani, Takayo Murase, Takashi Nakamura, Nobuaki Kobayashi, Noritake Hata, Kuniya Asai, Wataru Shimizu
Journal: Circulation (2018)

Background: Whether or not the xanthine oxydoreductase (XOR) activity is elevated in the acute phase of acute heart failure (AHF) remains unclear. Time-dependent changes in XOR after treatment for ...
A NEW CLINICAL SITUATION IN OUR DAY TO DAY: NONAGENARIANS AND STEMI
Authors: Pedro Luis Cepas Guillen, Javier Borrego-Rodriguez, Julio Echarte-Morales, Andrea Fernandez-Valledor, Paula Menendez-Suarez, Sara Vazquez Calvo, Ander Regueiro, I. Iglesias Garritz, Eduardo Flores, Armando Perez de Prado, Salvatore Brugaletta, Xavier Freixa, Felipe Fernandez-Vazquez, Manel Sabate
Journal: Journal of the American College of Cardiology (2020)
HEARTCARE: ADVANCING PRECISION MEDICINE THROUGH COMPREHENSIVE CARDIOVASCULAR GENETIC TESTING
Authors: Ginger Metcalf, David R. Murdock, Eric Venner, Mullai Murugan, Donna Muzny, Stacey Pereira, Eric Boerwinkle, Christie M. Ballantyne, Richard A. Gibbs
Journal: Journal of the American College of Cardiology (2020)
PROGNOSTIC IMPACT OF FRACTIONAL EXCRETION OF UREA NITROGEN AND URINE OSMOLALITY IN PATIENTS WITH ACUTE DECOMPENSATED HEART FAILURE
Authors: Yoshinori Iida, Haruhiko Abe, Masahiko Nakamura, Takuya Ohashi, Chieko Toriyama, Koutarou Takayasu, Tatsuhisa Ozaki, Syumpei Kosugi, Kazuya Shinouchi, Tsuyoshi Mishima, Motoo Date, Yasunori Ueda, Masaaki Uematsu, Yukihiro Koretsune
Journal: Journal of the American College of Cardiology (2020)
ONE MONTH DUAL ANTIPLATELET THERAPY IN HIGH BLEEDING RISK PATIENTS: PRIMARY RESULTS FROM THE ONYX ONE CLEAR STUDY
Authors: Ajay Kirtane, David E. Kandzari, Roxana Mehran, Matthew J. Price, Daniel I. Simon, Azeem Latib, Elvin Kedhi, Alexandre Abizaid, Stephen Worthley, Azfar Zaman, Lisa Bousquette, Lilian Lee, Te-Hsin Lung, Stephan Windecker, Gregg W. Stone
Journal: Journal of the American College of Cardiology (2020)
Improving Clinical Islet Transplantation Outcomes
Authors: Bart O. Roep
Journal: Diabetes Care (2020)

Transplantation of islets purified from donor pancreata is one of only a few clinical strategies that can reverse type 1 diabetes (T1D) and restore glycemic control (1–3). Significant progress has been made by improving transplantation strategies in areas including immune suppressive regimes, islet quality, transplanted β-cell mass and purity, and donor selection (4–6). However, while improved metabolic control and reduced glycemic side effects such as hypoglycemia persist long term in the majority of T1D patients, insulin independence beyond 1 year is only achieved in a minority of cases (2). Early loss of islet mass upon portal vein infusion is believed to have a major negative impact (7). Recurrence of insulitis, the hallmark of T1D immunopathogenesis leading to autoimmune mediated β-cell destruction, and islet allograft rejection pose additional therapeutic hurdles (8,9).

Recently, neutrophils were suggested as part of the innate immune system contributing to development of T1D (10). Chemokines produced by distressed islet tissue attract leukocytes to the site of implantation (Fig. 1). The chemokine CXCL8, produced by recruited and resident macrophages, attracts neutrophils carrying its receptors CXCR1/2 to the lesion. In this issue of Diabetes Care , Piemonti and colleagues (11) now report the results of a phase 3 clinical trial assessing whether interference in homing of leukocytes to the implanted islet graft using reparixin, a small molecule that interferes with CXCR1/2 signaling, may improve transplantation outcome. The rationale for this strategy is outstanding. Early studies in mice and humans were very encouraging. Treatment with reparixin prevented and reversed autoimmune diabetes in NOD mice and improved graft survival …
Bronchial neuroendocrine tumors: A retrospective review of management and outcomes in 116 patients.
Authors: Marinos Pericleous, Heather Lumgair, Johnathan Reiner, Laura Marelli, Martyn Caplin, Tim Meyer, Christos Toumpanakis
Journal: Journal of Clinical Oncology (2012)

e17543 Background: Bronchial neuroendocrine tumours, represent 1–3% of all primary lung tumours and 25% of all neuroendocrine tumours (NETs). They are classified into: typical carcinoids (TC), atypical carcinoids (AC), large cell neuroendocrine carcinomas (LCNEC) and small cell lung carcinomas (SCLC). The aim of our study was to assess diagnostic features, management and outcome, focusing on the differences between TC and AC. Methods: 116 patients were identified from our NET database. WHO histopathological classification was used. Follow-up was complete in all patients (mean follow-up 59.8 months). Disease-free survival (DFS), and progression-free survival (PFS) were evaluated for each therapy. Results: The average age of presentation was 55.30 years (range 16-85 years, M:F ratio=1:1.5). The commonest presenting symptom was cough (19%) followed by haemoptysis (18%). 36% were TC, 45% AC, and 19% LCNEC/SCLC. 16% TC and 28% AC patients had metastases at diagnosis. Octreoscan was positive in 76% TC and 66% AC. In 2 patients with TC and negative Octreoscan, Ga-68 Octreotate PET showed avid uptake in lung lesions. 46 patients had surgery. In 35 of AC, the disease relapsed (DFS=29.8 months) compared to 24% TC (DFS=48months). 12 patients received somatostatin analogues (SSTA) with PFS for TC 60 months and AC 21 months. 16 patients received systemic chemotherapy with PFS for TC 72 months and AC 21 months. 4/5 patients achieved disease stability with 90Yttrium-DOTAoctreotate. 5-years survival after surgery, chemotherapy or SSTA, was 91%, 86% and 81% respectively. Overall five year survival was 91% (100 % TC, 75% AC). Conclusions: AC and SCLC/LCLC more often present with metastatic disease with shorter DFS and PFS compared to TC. Molecular imaging is helpful for staging and predicting appropriateness for SSTA or radionuclide targeted therapy. Surgery confers the best survival rates. AC have higher relapse rates and metastatic potential. Further clinical trials are required to define the best treatment algorithm.
COMPARISON BETWEEN TWO DIFFERENT LOCAL HEMOSTASIS TECHNIQUES FOR DENTAL EXTRACTIONS IN PATIENTS ON DUAL ANTIPLATELET THERAPY: A WITHIN-PERSON, SINGLE-BLIND, RANDOMIZED TRIAL
Authors: Bruno Guardieiro, Marcela A. Santos-Paul, Rocío Salsoso, Talia Dalçóquio, Remo Furtado, Itamara L.I. Neves, Ricardo S. Neves, Cyrillo Cavalheiro Filho, Luciano Baracioli, Jose C. Nicolau
Journal: Journal of the American College of Cardiology (2020)
Validation of a five reagent immunohistochemistry assay for prognostication of estrogen-receptor expressing breast cancer
Authors: D. T. Ross, A. R. Frost, R. Beck, R. S. Seitz, B. Z. Ring
Journal: Journal of Clinical Oncology (2006)

10081 Background: We have previously reported the translation of gene expression data into a five reagent polyclonal antibody immunohistochemistry assay targeting p53, SLC7A5, NDRG1, HTF9C, and CEACAM5 whose staining results are combined using a Cox proportional hazard model for prognostication of estrogen receptor expressing breast cancer. Monoclonal antibodies targeting these genes have now been obtained and or produced. Methods: Paraffin blocks from 229 patients seen at the University of Alabama at Birmingham Clinical Cancer Center were assembled into tissue arrays and clinical follow-up data was collected by chart review. Immunohistochemical stains were performed and cases scored as positive or negative with the five monoclonal antibody assay. In order to further test the assays predictive value for assessing outcome, the prospectively defined Cox proportional hazard model and high, moderate, and low risk cutoffs were applied to the staining results on the estrogen receptor positive (ER+) patients for whom a assessment of death due to disease (DOD) and staining results for all five biomarkers were available. Results: The Kaplan-Meier estimates of outcome confirmed that the Cox model distinguished ER+ patients with poor outcomes. The five antisera algorithm identified high risk patients with a five year estimate of DOD of 41% compared to 20% for moderate and 9% for good (p=0.006) (79 patients total). In ER+ node negative patients the model identified high risk patients with a five year estimate of DOD of 50% compared to 18% for moderate and 5% for good (p=0.01) (40 patients total). The prognosticator was independent of age, pathological stage, and tumor size. Conclusions: A panel of five antibodies can significantly improve upon traditional prognosticators in predicting outcome for estrogen receptor positive breast cancer patients. This represents the third independent validation study performed on cohorts from different institutions. Retrospective studies on clinical trial cohorts and prospective studies should be performed to further establish the utility of this test in identifying early stage breast cancer patients at high risk for recurrence. [Table: see text]
Endoscopic ultrasound-guided antegrade stenting through a hilar cholangiocarcinoma associated with a severe biliary infection
Authors: Hirofumi Harima, Seiji Kaino, Yuko Fujimoto, Shogo Amano, Isao Sakaida
Journal: Endoscopy (2020)

The efficacy of endoscopic ultrasound-guided (EUS) antegrade stenting has been previously reported [1] [2]. We describe a rare and fatal complication of EUS antegrade stenting.
CLO20-060: Factors Associated with the Uptake of Adjuvant Pertuzumab in Patients with Stage I-III HER2-positive Breast Cancer: The University of Colorado Cancer Center Experience
Authors: Ericson Stoen, Jodi Kagihara, Peter Kabos, Christine Fisher, Jennifer R. Diamond
Journal: Journal of the National Comprehensive Cancer Network (2020)

"CLO20-060: Factors Associated with the Uptake of Adjuvant Pertuzumab in Patients with Stage I-III HER2-positive Breast Cancer: The University of Colorado Cancer Center Experience" published on 20 Mar 2020 by National Comprehensive Cancer Network.
Connectivity patterns between multiple allergen specific IgE antibodies and their association with severe asthma
Authors: Graham Roberts, Sara Fontanella, Anna Selby, Rebecca Howard, Sarah Filippi, Gunilla Hedlin, Bjorn Nordlund, Peter Howarth, Simone Hashimoto, Peter Brinkman, Louise J. Fleming, Clare Murray, Andrew Bush, Urs Frey, Florian Singer, Ann-Marie Malby Schoos, Wim van Aalderen, Ratko Djukanovic, K. Fan Chung, Peter J. Sterk, Custovic Adnan
Journal: Journal of Allergy and Clinical Immunology (2020)
Development of the Scalp Hair Assessment PRO™ measure for alopecia areata
Authors: K.W. Wyrwich, H. Kitchen, S. Knight, N.V.J. Aldhouse, J. Macey, F.P. Nunes, Y. Dutronc, N. Mesinkovska, J.M. Ko, B.A. King
Journal: British Journal of Dermatology (2020)

BackgroundValid patient‐reported outcome (PRO) measures are required to evaluate alopecia areata (AA) treatments.
Novel Mutations and Decreased Expression of the Epigenetic Regulator <i>TET2</i> in Pulmonary Arterial Hypertension
Authors: François Potus, Michael W. Pauciulo, Elina K. Cook, Na Zhu, Alexander Hsieh, Carrie L. Welch, Yufeng Shen, Lian Tian, Patricia Lima, Jeffrey Mewburn, Christine L. D’Arsigny, Katie A. Lutz, Anna W. Coleman, Rachel Damico, Brooke Snetsinger, Ashley Y. Martin, Paul M. Hassoun, William C. Nichols, Wendy K. Chung, Michael J. Rauh, Stephen L. Archer
Journal: Circulation (2020)

Background: Pulmonary arterial hypertension (PAH) is a lethal vasculopathy. Hereditary cases are associated with germline mutations in BMPR2 and 16 other genes; however, these mutations occur in &lt;25% of patients with idiopathic PAH and are rare in PAH associated with connective tissue diseases. Preclinical studies suggest epigenetic dysregulation, including altered DNA methylation, promotes PAH. Somatic mutations of Tet-methylcytosine-dioxygenase-2 ( TET2 ), a key enzyme in DNA demethylation, occur in cardiovascular disease and are associated with clonal hematopoiesis, inflammation, and adverse vascular remodeling. The role of TET2 in PAH is unknown. Methods: To test for a role of TET2 , we used a cohort of 2572 cases from the PAH Biobank. Within this cohort, gene-specific rare variant association tests were performed using 1832 unrelated European patients with PAH and 7509 non-Finnish European subjects from the Genome Aggregation Database (gnomAD) as control subjects. In an independent cohort of 140 patients, we quantified TET2 expression in peripheral blood mononuclear cells. To assess causality, we investigated hemodynamic and histological evidence of PAH in hematopoietic Tet2 -knockout mice. Results: We observed an increased burden of rare, predicted deleterious germline variants in TET2 in PAH patients of European ancestry (9/1832) compared with control subjects (6/7509; relative risk=6; P =0.00067). Assessing the whole cohort, 0.39% of patients (10/2572) had 12 TET2 mutations (75% predicted germline and 25% somatic). These patients had no mutations in other PAH-related genes. Patients with TET2 mutations were older (71±7 years versus 48±19 years; P &lt;0.0001), were more unresponsive to vasodilator challenge (0/7 versus 140/1055 [13.2%]), had lower pulmonary vascular resistance (5.2±3.1 versus 10.5±7.0 Wood units; P =0.02), and had increased inflammation (including elevation of interleukin-1β). Circulating TET2 expression did not correlate with age and was decreased in &gt;86% of PAH patients. Tet2 -knockout mice spontaneously developed PAH, adverse pulmonary vascular remodeling, and inflammation, with elevated levels of cytokines, including interleukin-1β. Long-term therapy with an antibody targeting interleukin-1β blockade resulted in regression of PAH. Conclusions: PAH is the first human disease related to potential TET2 germline mutations. Inherited and acquired abnormalities of TET2 occur in 0.39% of PAH cases. Decreased TET2 expression is ubiquitous and has potential as a PAH biomarker.
SEX DIFFERENCES IN PATIENT SELECTION AND OUTCOMES OF SEPTAL REDUCTION THERAPIES FOR OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY IN THE UNITED STATES
Authors: Jayakumar Sreenivasan, Urvashi Hooda, Simrat Kaur, Sachit Sharma, Wilbert S. Aronow, Howard A. Cooper, Srihari Naidu, Julio Panza
Journal: Journal of the American College of Cardiology (2020)